Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall
RCKT•Rocket Pharmaceuticals reported a third-quarter net loss of $49.2 million, or $0.43 per share, as lower R&D expenses helped narrow its loss from a year earlier. The company expects cash and investments to fund operations into Q3 2028.
1. Quarterly results
Rocket Pharmaceuticals reported a third-quarter net loss of $49.2 million, or $0.43 per share. Lower compensation and manufacturing expenses drove a decrease in R&D costs, partially offset by higher laboratory and clinical trial costs.
2. Pipeline and outlook
The company said it achieved FDA alignment on a pivotal Phase 2 trial for RP-A501 in Danon disease and expects to complete trial dosing by mid-2027. KRESLADI reached commercial readiness, with treatment centers activated.
3. Cash runway
Rocket expects cash and investments to fund operations into Q3 2028. Additional borrowings could extend its cash runway into 2029, subject to conditions.
